Public Release:  Engineered pea seeds protect against parasites

BioMed Central

A breed of pea seeds has been created that contains antibodies against coccidiosis, a disease caused by a parasite that attacks chickens. Researchers writing in the open access journal BMC Biotechnology describe the development of the GM seeds, and demonstrate their effectiveness in preventing this economically important illness.

Sergej Kiprijanov worked with a team of researchers from Novoplant GmbH, Germany, to develop the seeds. He said, "There are a few major issues precluding the use of monoclonal antibodies for passive immunization of chickens against infectious diseases, primarily the costs of antibody production and treatment. Treatment costs are high because antibodies must normally be given intravenously; otherwise they are destroyed in the animal's gut. By expressing the antibodies inside pea seeds, they are protected from this degradation - allowing our system to dramatically reduce treatment costs".

The researchers found that chickens infected with the parasite and allowed to eat the antibody-containing pea seeds, shredded into their feed, were significantly less likely to contract coccidiosis than chickens fed ordinary pea seeds in their fodder. Kiprijanov said, "Compared with methods of active vaccination, the passive immunization strategy described here is an easy and non-invasive method to use in commercial settings. The cost of production is comparatively low, utilizing current agriculture technologies, and the strategy can be used in combination with other antiparasitic agents".

###

Notes to Editors

1. Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens
Jana Zimmermann, Isolde Saalbach, Doreen Jahn, Martin Giersberg, Sigrun Haehnel, Julia Wedel, Jeanette Macek, Karen Zoufal, Gerhard Glunder, Dieter Falkenburg and Sergej M Kiprijanov
BMC Biotechnology (in press)

During embargo, article available here: http://www.biomedcentral.com/imedia/2111458107274596_article.pdf?random=454013

After the embargo, article available at journal website: http://www.biomedcentral.com/bmcbiotechnol/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication

2. BMC Biotechnology is an open access journal publishing original peer-reviewed research articles in the manipulation of biological macromolecules or organisms for use in experimental procedures, cellular and tissue engineering or in the pharmaceutical, agricultural biotechnology and allied industries. BMC Biotechnology (ISSN 1472-6750) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, Scopus, EMBASE, Thomson Reuters (ISI) and Google Scholar.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.